A Single-dose, Open-label, Pharmacokinetic Study of Belapectin (GR-MD-02) in Subjects With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 16, 2020

Primary Completion Date

March 9, 2022

Study Completion Date

March 9, 2022

Conditions

Hepatic Impairment

Interventions

DRUG

belapectin

intravenous

Trial Locations (4)

Texas Liver Institute, San Antonio

Pinnacle Clinical Research, San Antonio

Inland Empire Clinical Trials, Rialto

Clinical Pharmacology of Miami, Inc, Miami